报价延迟最少15分钟:2026/08/05 18:36 EDT
盘后时段
|
||||
|
0.3479 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3402
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.46/--
|
|
企业价值
7.95M
|
| 资产负债 |
|
每股账面净值
0.13
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
301.65K
|
|
每股收益
0.03
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the US and China, with China generating the maximum sales. |
